MYT1L单倍剂量不足导致孤独症相关表型,遗传与药物干预可逆转
该研究考察MYT1L缺陷在人类神经元和小鼠中的作用,发现突变小鼠出现神经发育延迟、皮层变薄、行为表型及类似孤独症患者的基因表达改变。MYT1L缺失激活WNT和NOTCH靶基因,化学抑制可挽救体外神经发生延迟;SCN5A上调导致神经元过度活跃,敲低SCN5A、过表达MYT1L或急性应用拉莫三嗪可挽救电生理与行为缺陷。
要点
- MYT1L缺陷同时引起发育性和出生后神经缺陷
- SCN5A上调及神经元过度活跃是关键可干预靶点
- 急性药物干预可在成年期正常化电生理和行为表型
核心结论
- MYT1L单倍剂量不足通过发育性和出生后机制导致孤独症相关神经表型,急性干预可逆转电生理和行为缺陷。
研究设计与样本
- 研究检查MYT1L缺陷在人类神经元和小鼠中的效应,使用突变小鼠进行神经发育、行为及基因表达分析。
主要发现
- 突变小鼠 exhibit 神经发育延迟、皮层变薄、行为表型及类似孤独症患者的基因表达改变。
- MYT1L靶基因包括WNT和NOTCH在MYT1L耗竭时被激活,其化学抑制可挽救体外延迟的神经发生。
- MYT1L缺陷上调主要心脏钠通道SCN5A并导致神经元过度活跃,shRNA介导的SCN5A敲低或出生后神经元中MYT1L过表达可恢复。
- 急性应用钠通道阻滞剂拉莫三嗪挽救体外电生理缺陷和体内行为表型。
临床怎么用
- SCN5A和神经元过度活跃可能作为MYT1L相关孤独症表型的干预靶点。
- 拉莫三嗪等钠通道阻滞剂在成年期急性干预可能正常化电生理和行为表型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MYT1L is an autism spectrum disorder (ASD)-associated transcription factor that is expressed in virtually all neurons throughout life. How MYT1L mutations cause neurological phenotypes and whether they can be targeted remains enigmatic. Here, we examine the effects of MYT1L deficiency in human neurons and mice. Mutant mice exhibit neurodevelopmental delays with thinner cortices, behavioural phenotypes, and gene expression changes that resemble those of ASD patients. MYT1L target genes, including WNT and NOTCH, are activated upon MYT1L depletion and their chemical inhibition can rescue delayed neurogenesis in vitro. MYT1L deficiency also causes upregulation of the main cardiac sodium channel, SCN5A, and neuronal hyperactivity, which could be restored by shRNA-mediated knockdown of SCN5A or MYT1L overexpression in postmitotic neurons. Acute application of the sodium channel blocker, lamotrigine, also rescued electrophysiological defects in vitro and behaviour phenotypes in vivo. Hence, MYT1L mutation causes both developmental and postmitotic neurological defects. However, acute intervention can normalise resulting electrophysiological and behavioural phenotypes in adulthood.
引用
- Weigel B, Tegethoff JF, Grieder SD, et al. MYT1L haploinsufficiency in human neurons and mice causes autism-associated phenotypes that can be reversed by genetic and pharmacologic intervention. Mol Psychiatry. 2023. PMID: 36782060. doi:10.1038/s41380-023-01959-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。